Silodosin for benign prostatic hyperplasia

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 302-310

  Cantrell, Matthew A ^a,b   Bream Rouwenhorst, Heather R ^a,c   Hemerson, Phyllis ^a,d   Magera Jr , James S ^e  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Mercy Hospital Iowa City   (United States)

^e Mercy Hospital   (United States)

Author keywords

Benign prostatic hyperplasia; Silodosin

Indexed keywords

ALCOHOL; ALDEHYDE DEHYDROGENASE; ALFUZOSIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; DOXAZOSIN; ERYTHROMYCIN; FLUCONAZOLE; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; PLACEBO; PRAZOSIN; PROBENECID; RITONAVIR; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; VALPROIC ACID; VERAPAMIL;

AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CATARACT EXTRACTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DISSOCIATION CONSTANT; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; EJACULATION DISORDER; GLUCURONIDATION; HEADACHE; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; INTERNATIONAL PROSTATE SYMPTOM SCORE; INTRAOPERATIVE FLOPPY IRIS SYNDROME; IRIS DISEASE; JAUNDICE; KIDNEY DISEASE; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PURPURA; QUALITY OF LIFE; RASH; RECEPTOR UPREGULATION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; THIRST; TINNITUS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINE FLOW RATE; URINE INCONTINENCE;

ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; INDOLES; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 76149126999     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M320     Document Type: Review

References (35)

1. Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med 1996;11:513-8.
2. Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis. J Urol 1992;147:1167-70.
3. McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms. Am J Med 2005;118:1331-9. DOI 10.1016/j.amjmed.2004.12.033
4. Meyer MD, Alteabach RJ, Basha FZ, et al. Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J Med Chem 2000; 43:1586-603. DOI 10.1021/jm990567u
5. Kenny BA, Miller AM, Williamson IJ, et al. Evaluation of the pharmacological selectivity profile of alpha-1-adrenoceptor antagonists at prostatic alpha-1-adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996;118:871-8.
6. Taguchi K, Saitoh M, Sato S, et al. Effects of tamsulosin metabolites at alpha-1-adrenoceptors subtypes. J Pharmacol Exp Ther 1997;280:1-5.
7. Shibata K, Foglar R, Horie K, et al. KMD -3213, a novel, potent, alpha 1aadrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48: 250-8.
8. Thiyagarajan M. α-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology 2002;65:119-28.
9. Product information. Rapaflo (silodosin). Corona, CA: Watson Pharmaceuticals, Inc., October 2008.
10. 1A-adrenoreceptorselective antagonist for treating benign prostatic hyperplasia: results of a Phase III randomized, placebo controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24. DOI 10.1111/j.1464-410X.2006.06448.x
11. Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 2008;15:992-6. DOI 10.1111/j.1442-2042.2008.02154.x
12. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40. Epub 16 Apr 2009. DOI 10.1016/j.juro.2009.02.034
13. 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16:1955-64. DOI 10.1517/13543784.16.12.1955
14. 1A-adrenoceptor antagonist silodosin (KMD -3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung 2006;56:682-7.
15. Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new alpha 1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008;15:915-8. DOI 10.1111/j.1442-2042.2008.02136.x
16. Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med 2008;5:2185-90. Epub 9 Apr 2007. DOI 10.1111/j.1743-6109.2008.00779.x
17. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73. DOI 10.1016/j.jcrs.2005.02.027
18. 1-adrenergic receptor antagonists. Ann Pharmacother 2008;42: 558-63. Epub 25 Mar 2008. DOI 10.1345/aph.1K679
19. 1-adenoreceptor antagonist, in human prostate and vasculature. J Urol 2000;164:578-83. DOI 10.1016/S0022-5347(05)67426-5
20. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
21. Mudiyala R, Ahmed A. Effect of terazosin on clinical benign prostatic hyperplasia in older adults. J Am Geriatr Soc 2003;51:424-6.
22. Lowe FC. Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia - related lower urinary tract symptoms. Clin Ther 2004;26:1701-13. DOI 10.1016/j.clinthera.2004.11.006
23. Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8. DOI 10.1016/j.urology.2004.07.031
24. Drugstore.com. http://drugstore.com (accessed 2010 Jan 20).
25. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481-8. DOI 10.1159/000019639
26. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59.
27. Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Prostate Cancer Prostatic Dis 2007;10:155-9.
28. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900. DOI 10.1016/S0090-4295(98)00126-5
29. Elhilali M, Emberton M, Matzkin H, et al.; ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006;97:513-9. DOI 10.1111/j.1464-410X.2005.05962. x
30. Ichioka K, Ohara H, Terada N, et al. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol 2004;11:870-5. DOI 10.1111/j.1442-2042.2004.00913.x
31. Palacio A, Hernández C, Marqués A, Prats J, Espinosa FJ. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report. Arch Esp Urol 2004;57:451-60.
32. Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol 2005;173:155-7.
33. Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-21. Epub 21 Dec 2007. DOI 10.1016/j.juro.2007.09.084
34. Barkin J, Roehrborn CG, Siami P, et al.; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009;103:919-26. Epub 23 Feb 2009. DOI 10.1111/j.1464-410X.2009.08196.x
35. McConnell JD, Roehrborn CG, Bautista OM, et al.; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. DOI 10.1056/NEJMoa030656